Allergic rhinitis
Conditions
Interventions
Treatment:injection of HDM
Control:Placebo injection
Sponsors
The Second Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Aged 18 to 55 years, with moderate or severe allergic rhinitis that can not be well controlled by drugs; with positive reaction to mite extract in skin prick tests; with Der.p sIgE level that above grade three; voluntary subjects that can obtain informed consent.
Exclusion criteria
Exclusion criteria: Pregnancy, breast-feeding women; associated with asthma; patients with acute or chronic sinusitis or other nasal organic disease; with other diseases that require long-term use of hormones and immunosuppressive drugs; suffering from other diseases in heart, lung,or kidney; use of ß-blocker; other condition that is not suitable in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nasal symptom scores;result of nasal provocation test by allergen;result of skin test by allerge; | — |
Secondary
| Measure | Time frame |
|---|---|
| rhinoconjunctivitis quality of life questionnaire;total IgE in serum;specific IgE in serum;specific IgG4 in serum;cytokines in serum, such as IL-10,IL-13,IL-4,IFN-?, IL-17, etc.; | — |
Countries
China
Contacts
Public ContactAilin Tao
The Second Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed